Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

(2022) Brian A. Bergmark et al.   CIRCULATION

ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia

(2021) Laurens F. Reeskamp et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction

(2021) Aleesha Shaik et al.   CARDIOVASCULAR DRUGS AND THERAPY

Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia

(2021) Zahid Ahmad et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis

(2021) Robert J. Sanchez et al.   Lipids in Health and Disease

New Therapies for Lowering Triglyceride-Rich Lipoproteins

(2021) Robert S. Rosenson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Recognition and Treatment of Homozygous Familial Hypercholesterolemia by Primary Care Physicians: a Survey from the National Lipid Association

(2020) Linda Hemphill et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Angiopoietin-like protein 3 (ANGPTL3) governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance

(2020) Rene C. Adam et al.   JOURNAL OF LIPID RESEARCH

Genetics of Hypertriglyceridemia

(2020) Jacqueline S. Dron et al.   Frontiers in Endocrinology

Evinacumab for Homozygous Familial Hypercholesterolemia

(2020) Frederick J. Raal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD

(2019) Marja-Riitta Taskinen et al.   Current Atherosclerosis Reports

Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia

(2019) Zahid Ahmad et al.   CIRCULATION

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Clinical review on triglycerides

(2019) Ulrich Laufs et al.   EUROPEAN HEART JOURNAL

Severe hypertriglyceridemia is primarily polygenic

(2018) Jacqueline S. Dron et al.   Journal of Clinical Lipidology

Elevated Serum Triglycerides in the Prognostic Assessment of Acute Pancreatitis

(2017) Qian Wang et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

ANGPTL3 Deficiency and Protection Against Coronary Artery Disease

(2017) Nathan O. Stitziel et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia

(2017) Daniel Gaudet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

(2017) Frederick E. Dewey et al.   NEW ENGLAND JOURNAL OF MEDICINE

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

(2015) Terry A. Jacobson et al.   Journal of Clinical Lipidology

Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease

(2014) Robert S. Rosenson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Apolipoproteins C-I and C-III Inhibit Lipoprotein Lipase Activity by Displacement of the Enzyme from Lipid Droplets

(2013) Mikael Larsson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus

(2012) Peter A Banks et al.   GUT

Prevalence of Severe (500 to 2,000 mg/dl) Hypertriglyceridemia in United States Adults

(2011) Jennifer B. Christian et al.   AMERICAN JOURNAL OF CARDIOLOGY

Exome Sequencing,ANGPTL3Mutations, and Familial Combined Hypolipidemia

(2010) Kiran Musunuru et al.   NEW ENGLAND JOURNAL OF MEDICINE